Banner Image Banner Image

Investors
& Media

Press Releases

Press Releases

All Releases
TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting and Exposition
Proprietary triplet of U2 plus TG-1701 (BTK inhibitor) induced 86% ORR (6 of 7) in patients with relapsed/refractory NHL and CLL at the lowest dose of TG-1701 tested Single agent TG-1701 induced responses at multiple dose levels (including the lowest dose tested) across multiple B-cell diseases
Dec 09, 2019
TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition
100% overall response rate ( ORR ) in relapsed/refractory CLL patients treated with U2 (umbralisib + ublituximab) plus venetoclax at cycle 7 (n=13) 100% of patients (n=9) achieved undetectable MRD in the peripheral blood after 12 months of therapy and 78% achieved undetectable MRD in bone marrow
Dec 08, 2019
TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition
Investor and analyst event to be held on Monday, December 9, 2019 at 7:30 PM ET at the Hyatt Regency Orlando featuring a fireside chat with leading clinical investigators NEW YORK , Dec. 06, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of triple therapy
Dec 06, 2019
TG Therapeutics to Present at the Jefferies London Healthcare Conference
Presentation scheduled for Wednesday, November 20, 2019 11:20 AM GMT NEW YORK , Nov. 18, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will present at the Jefferies London
Nov 18, 2019
TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
Conference call to be held today, Tuesday, November 12, 2019 at 8:30 AM ET  NEW YORK , Nov. 12, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2019 and recent company developments. Michael S.
Nov 12, 2019
TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update
Conference Call to be held Tuesday, November 12, 2019 at 8:30 AM ET NEW YORK , Nov. 08, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday, November 12, 2019 at 8:30 AM ET to discuss results for the third quarter of 2019 and
Nov 08, 2019
TG Therapeutics Announces Triple Combination Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition
100% overall response rate ( ORR ) in relapsed/refractory CLL patients (n=9) treated with U2 (umbralisib + ublituximab) plus venetoclax, with all patients at 12 months achieving MRD negativity (n=5) Proprietary triplet of U2 plus TG-1701 (BTK inhibitor) induced 100% ORR (n=3) in patients with
Nov 06, 2019
TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma
Follicular lymphoma cohort met the primary endpoint of overall response rate (ORR) Umbralisib monotherapy appeared to be well tolerated with a safety profile consistent with previous reports TG plans to present the data at a future medical conference and discuss the results with the FDA Conference
Oct 28, 2019
TG Therapeutics Announces Final Long-Term Results from the Phase 3 GENUINE Study Demonstrated that Ublituximab in Combination with Ibrutinib Improved Progression-Free Survival in Patients with High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia as
Combination was well tolerated with no new safety signals identified with median follow-up of >4 years GENUINE met its primary endpoint of improved overall response rate, as previously reported TG plans to present these final data at a future medical conference and share these results with the FDA
Oct 24, 2019
TG Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
Presentation scheduled for today, Wednesday, October 2, 2019 at 4:10 PM ET   NEW YORK , Oct. 02, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat
Oct 02, 2019
Displaying 1 - 10 of 45